Global Apheresis Systems Market Size By Type (Semi-Automatic, Fully Automatic), By Application (Hospitals, Blood Center), By Region, And Segment Forecasts, 2023 to 2032

The Global Apheresis Systems Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 3.9 billion by 2031, growing at a CAGR of 7.8% during the forecast period from 2023 to 2031. The increasing prevalence of chronic diseases, advancements in blood component separation technologies, and the growing use of apheresis in therapeutic and donor-based procedures are the primary growth drivers. Apheresis systems are critical in hematology, nephrology, and oncology treatments, enabling efficient separation of blood components for both therapeutic and donation purposes.

Drivers:

1. Rising Prevalence of Chronic and Autoimmune Diseases:

An increasing incidence of diseases such as leukemia, multiple myeloma, myasthenia gravis, and rheumatoid arthritis is driving demand for therapeutic apheresis procedures. The ability of apheresis to manage symptoms by removing pathogenic substances has made it a key tool in clinical practice.

2. Growth in Blood Donation and Plasma Collection Activities:

The global rise in blood donations, coupled with increasing awareness about plasma-derived therapies, has led to a surge in demand for apheresis equipment. Governments and organizations are promoting voluntary plasma donation programs, contributing to market expansion.

3. Technological Advancements in Apheresis Systems:

Modern apheresis machines offer enhanced safety, accuracy, and comfort, with features like real-time monitoring and automated flow adjustment. These innovations are improving procedural outcomes and operational efficiency in hospitals and blood centers.

Restraints:

1. High Cost of Apheresis Systems and Procedures:

The upfront investment in apheresis equipment and the recurring operational costs are significant, which can restrict adoption, particularly in developing regions or small healthcare facilities.

2. Limited Availability of Trained Personnel:

Apheresis procedures require specialized knowledge and training. The lack of skilled technicians and medical staff can hinder adoption, especially in rural or under-resourced areas.

Opportunity:

1. Expanding Applications in Therapeutic Apheresis:

Emerging uses of apheresis for treating neurological disorders, metabolic diseases, and COVID-19-related complications are opening new frontiers. Research into the use of apheresis for personalized medicine and regenerative therapies further boosts market prospects.

2. Growing Demand in Emerging Markets:

Rising healthcare expenditure, improving infrastructure, and greater awareness in Asia-Pacific and Latin America present lucrative growth opportunities for market players.

Market by System Type Insights:

The Centrifugal Apheresis Systems segment held the largest market share in 2023, favored for its efficiency in separating components using high-speed rotation. These systems are widely used in both therapeutic and donor-based settings. Meanwhile, Membrane Filtration Apheresis Systems are expected to witness the fastest growth due to their selective filtration capabilities and expanding clinical applications.

Market by End-Use Insights:

Hospitals and Clinics dominated the market in 2023, accounting for more than 45% of the global revenue share. Their ability to provide specialized therapeutic apheresis services for in-patient and emergency treatments makes them leading end-users. Blood Collection Centers are also rapidly growing, driven by increased plasma demand and donor mobilization campaigns.

Market by Regional Insights:

North America led the global apheresis systems market in 2023, attributed to a strong healthcare system, supportive reimbursement policies, and high disease awareness. Asia-Pacific is projected to be the fastest-growing region during the forecast period, driven by improving healthcare access, a growing aging population, and increased investment in public health initiatives.

Competitive Scenario:

Key players in the global apheresis systems market include Terumo BCT, Inc., Haemonetics Corporation, Fresenius Kabi, Asahi Kasei Medical Co., Ltd., Kaneka Corporation, B. Braun Melsungen AG, Baxter International Inc., Cerus Corporation, and Medica S.p.A. These companies focus on new product development, strategic partnerships, and geographic expansion.

Key Developments:

2023: Haemonetics Corporation launched its latest plasma collection system integrating AI-based donor monitoring features.

2024: Terumo BCT entered a collaboration with a Japanese biotech firm to expand therapeutic apheresis solutions in Asia.

2025: Fresenius Kabi received CE approval for its next-gen automated apheresis platform designed for outpatient centers.

Scope of Work – Global Apheresis Systems Market

Report Metric Details

Market Size (2023) USD 2.1 billion

Projected Market Size (2031) USD 3.9 billion

CAGR (2023-2031) 7.8%

Market Segments System Type (Centrifugal, Membrane Filtration), End-Use (Hospitals, Blood Centers, Research Institutes), Region

Growth Drivers Chronic disease prevalence, blood donation trends, technological advancements

Opportunities Therapeutic apheresis expansion, emerging market demand

FAQs:

1) What is the current market size of the Global Apheresis Systems Market?

The market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Apheresis Systems Market?

Key drivers include the rising prevalence of chronic diseases and the increasing use of apheresis in blood donation and therapeutic applications.

3) Which is the largest region during the forecast period in the Global Apheresis Systems Market?

North America is the largest regional market, with Asia-Pacific expected to grow at the fastest rate.

4) Which segment accounted for the largest market share in Global Apheresis Systems Market?

The Centrifugal Apheresis Systems segment held the largest market share in 2023.

5) Who are the key market players in the Global Apheresis Systems Market?

Major players include Terumo BCT, Haemonetics Corporation, Fresenius Kabi, Asahi Kasei Medical, and Baxter International.